CancerVax

About the offering

10 million people died last year because the body does not easily recognize and kill cancer cells. However, the body is very good at killing diseases that it recognizes, such as measles. Our unique pre-clinical technology disguises cancer cells to look like measles and “tricks” the body into killing them. REASONS TO INVEST Reasons Icon Previously raised $5.6 million in venture and crowdfunding. Our novel pre-clinical technology disguises cancer cells to look like well-immunized diseases, such as measles, and “tricks” the body into killing them with precision. Reasons Icon A world-class science team that has created multiple successful drugs that have gone to market. Reasons Icon A purpose-driven company with huge market potential. According to the World Health Organization, cancer is the second leading cause of death globally and was responsible for 10 million deaths in 2023. According to a 2024 report from Statista, the global cancer immunotherapy market will grow from $83 billion in 2023 to $231 billion by 2031.* the pitch A Universal Cancer Treatment Platform CancerVax is a pre-clinical biotech company developing a Universal Cancer Treatment Platform designed to target and eliminate cancer cells while leaving healthy cells unharmed. Our technology harnesses artificial intelligence to DETECT, MARK, and KILL cancer cells by disguising them as known pathogens, like measles, to trigger a natural immune response. With a seasoned scientific team and promising early-stage research, we envision a future where treating cancer will be as simple as getting a shot. We have assembled a world-class team of experienced cancer scientists and advisors to help develop our novel cancer technology. the problem & OUR SOLUTION Breakthrough Technology Cancer remains one of the deadliest diseases worldwide, claiming 10 million lives in 2023 alone (source: WHO). Traditional treatments like chemotherapy, radiation, and surgery come with severe side effects and inconsistent success rates. Despite advancements in immunotherapy, current therapies struggle to generate a strong or lasting immune response, leaving patients with limited options. The Problem The body’s immune system is very good at killing foreign pathogens, such as the measles virus. Unfortunately, it’s not very good at killing cancer cells, because cancer cells were originally healthy cells. This is why cancer grows undetected by the immune system and is so hard to treat. Our Solution CancerVax is pioneering a novel approach that tricks the immune system into identifying and attacking only cancer cells. Our technology forces cancer cells to produce proteins that mimic those of well-immunized diseases, like measles or chickenpox. The immune system, already trained to fight these diseases, then rapidly eliminates the disguised cancer cells. This innovative method leverages AI-powered detection and a two-step targeting system, providing a precise and potentially more effective treatment. Our technology is packaged into a nanoparticle that is programmed to seek out only cancer cells and uses a novel 2-step strategy to precisely detect cancer cells. Step 1 - Detect cell surface markers outside the cell (Marker1) Step 2 - Detect cancer genetic signatures inside the cell (Marker2) the market & our Early-Stage Validation The Market Cancer is the second leading cause of death globally, with 1.95 million new cases diagnosed in the U.S. in 2023 (American Cancer Society). The global cancer immunotherapy market is projected to grow from $83 billion in 2023 to $231 billion by 2031 (Statista), reflecting increasing demand for innovative treatment options. Our Early-Stage Validation CancerVax is a pre-clinical biotech company with successful in-vitro test results. Our nanoparticle-based cancer vaccine technology is being developed in collaboration with leading scientific teams and biotech partners, including Flashpoint Therapeutics and Cytiva. We believe we are on track to complete animal studies by Q1 2026, marking a crucial step toward clinical trials. We are developing a novel Universal Cancer Treatment Platform designed to be customizable as off-the-shelf injections to treat many types of cancer. Powered by artificial intelligence, our revolutionary approach DETECTS, MARKS, and KILLS only cancer cells using the body’s immune system. Other immunotherapies have had limited success trying to “teach” the immune system how to recognize cancer cells. Our approach is to make cancer cells look like a common disease that it already recognizes, such as measles, and “trick” the body into killing these “disguised” cancer cells. We envision a day when treating cancer will be as simple as getting a shot – it’s a better way to treat cancer. Competitors & What Makes Us Different Current cancer treatments rely on surgery, chemotherapy, and radiation, which attack both cancerous and healthy cells, causing severe side effects. In contrast, modern immunotherapies like Keytruda (Merck) and Opdivo (Bristol Myers Squibb) attempt to activate the immune system but often produce only short-lived or weak responses. What Makes Us Different CancerVax’s approach stands apart by not just stimulating the immune system but actively disguising cancer cells as a known pathogen. This method allows the immune system to respond immediately and aggressively, potentially leading to more effective and longer-lasting results than traditional immunotherapies. Achievements & Recognition CancerVax’s novel approach has been recognized by top cancer researchers and has attracted a world-class advisory board of leading scientists in oncology, immunology, and nanotechnology. Our development partners, including Flashpoint Therapeutics and Cytiva, are leaders in advanced cancer research and drug delivery systems. Early lab results have successfully validated our Smart mRNA technology in actual cancer cells, marking a significant milestone toward clinical trials. why invest Join Us On Our Journey! CancerVax is developing a novel and promising approach to cancer treatment that will harness the body’s immune system to eliminate only cancer cells. With a global cancer market valued in the hundreds of billions, a strong scientific team, and early-stage validation, CancerVax presents a unique opportunity to be part of a potential breakthrough in cancer treatment. Be part of the future of cancer treatment. Invest in CancerVax today. THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

FAQ